Fortrea Holdings (FTRE) EPS (Basic) (2022 - 2026)

Fortrea Holdings' (FTRE) quarterly EPS (Basic) came in at -$0.14 in Q2 2026, up 44.78% on a QoQ basis from -$0.25 in Q1 2026.

Analysis

Fortrea Holdings (FTRE) EPS (Basic) (2022 - 2026) Analysis & Trends

Fortrea Holdings (FTRE) has 4 years of EPS (Basic) data on file, last reported at -$0.14 in Q2 2026.

Quarterly EPS (Basic) changed N/A year-over-year to -$0.14 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$0.39 (down 1165.75% YoY) and the FY2024 annual result came in at -$0.64, down 970.06% from the prior year.
EPS (Basic) grew to -$0.14 in Q2 2026, from -$0.25 in the prior quarter.
In the past five years, EPS (Basic) ranged from a high of $0.75 in Q2 2022 to a low of -$0.44 in Q2 2024.
A 4-year average of $0.02 and a median of -$0.07 in 2023 frame the typical range for EPS (Basic).
The widest YoY moves for EPS (Basic): up 313.57% in 2024, down 769.61% in 2024.
Tracing FTRE's EPS (Basic) over 4 years: stood at -$0.15 in 2022, then soared by 56.62% to -$0.07 in 2023, then surged by 313.57% to $0.14 in 2024, then plunged by 198.13% to -$0.14 in 2026.
The last three EPS (Basic) figures came in at -$0.14 (Q2 2026), -$0.25 (Q1 2026), and $0.14 (Q4 2024), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.27 Bn	131.42 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn	12.62
3	Argenx Se	63.45 Bn	58.27 Bn	1.37 Bn	7.70
4	Moderna	57.73 Bn	52.59 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.08 Bn	44.08 Bn	-	-3.06
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.14 Bn	31.84 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	0.18
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	-0.06
10	Fortrea Holdings	1.72 Bn	1.55 Bn	139.20 Mn	-0.14

Historic Data

Download Data